Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

Podcast TCTMD Talking Points

The ENVISAGE-TAVI AF Trial

December 07, 2022

News Daily News

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

Todd Neale

November 23, 2022

News Daily News

Apixaban Again Linked to Less Bleeding in AF Patients

Michael O'Riordan

October 31, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

L.A. McKeown

February 22, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

Video

» Interview

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

May 4, 2022

Advertisement

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

The ENVISAGE-TAVI AF Trial

Slight Risk of Interstitial Lung Disease Seen With Certain DOACs

Apixaban Again Linked to Less Bleeding in AF Patients

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

What’s Going to Be Hot at ESC 2022?

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Fewer Diabetic Complications Seen When NOACs Given for AF

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content